Estimating Medicare and Patient Savings From the Use of Bevacizumab for the Treatment of Exudative Age-related Macular Degeneration.

@article{Rosenfeld2018EstimatingMA,
  title={Estimating Medicare and Patient Savings From the Use of Bevacizumab for the Treatment of Exudative Age-related Macular Degeneration.},
  author={Philip J. Rosenfeld and Matthew A Windsor and William J Feuer and Sissi J J Sun and Kevin D. Frick and Eric A Swanson and David Huang},
  journal={American journal of ophthalmology},
  year={2018},
  volume={191},
  pages={
          135-139
        }
}
PURPOSE The Medicare cost savings from the use of bevacizumab in the United States for the treatment of exudative age-related macular degeneration (AMD) were estimated by replacing the use of bevacizumab with ranibizumab and aflibercept. DESIGN Retrospective trend study. METHODS Main outcome measures were spending by Medicare as tracked by Current… CONTINUE READING